YD Bio (YDES) Enterprise Value (2024 - 2025)
YD Bio's (YDES) quarterly Enterprise Value came in at -$6.0 million in Q4 2025, down 91.8% year-on-year from -$73.2 million in Q4 2024, and down 1179.52% on a QoQ basis from -$469520.0 in Q2 2025.
YD Bio (YDES) Enterprise Value (2024 - 2025) Analysis & Trends
YD Bio (YDES) has 2 years of Enterprise Value data on file, last reported at -$6.0 million in Q4 2025.
- On a quarterly basis, Enterprise Value fell 91.8% year-over-year to -$6.0 million in Q4 2025; TTM through Dec 2025 was -$6.0 million, a 91.8% decrease from a year earlier, with the FY2025 full-year figure at -$6.0 million, down 91.8% from the prior year.
- Enterprise Value for Q4 2025 stood at -$6.0 million, down from -$469520.0 in the prior quarter.
- Over the last five years, Enterprise Value for YDES reached as high as -$469520.0 in Q2 2025 and fell as low as -$6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | YD Bio | 157.46 Mn | 151.45 Mn | - | -6.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.01 Mn |
| Jun 30, 2025 | -469,520.00 |
| Dec 31, 2024 | -3.13 Mn |